Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanamide SCHEMBL6388908 | 0.85 | GUCY1A1 (0.32) | — | |
| SCHEMBL6394178 | 0.84 | CA14 (0.31) | — | |
| SCHEMBL6389106 | 0.76 | ACACB (0.43) | EPHX2NPC1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL8744579 | 0.76 | ACLY (0.38) | CYP3A4 | |
| SCHEMBL6387917 | 0.73 | ALDH1A1 (0.39) | EPHX2NPC1ALDH1A1ALOX12RAB9A | |
| SCHEMBL12094533 | 0.73 | ACACB (0.49) | — | |
| Cyanamide SCHEMBL6392049 | 0.73 | FFAR1 (0.37) | EPHX2 | |
| SCHEMBL10267247 | 0.71 | — | — | |
| SCHEMBL12092684 | 0.71 | ACACB (0.54) | — | |
| SCHEMBL2737118 | 0.71 | ACACB (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | claimed |
| WO-2005068420-A1 | UREA AND THIOUREA COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | PNLIP, FABP2, GPR119 | EPHX2 3605/4885NPC1 390/4885ALDH1A1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.